Veeva Systems
VEEV NYSE· Health Care Technology
Last close · Oct 26, 2026
$318.18
KIRA · Stoqly’s AI analyst, in plain words
- Veeva Systems had $3.2B of revenue in fiscal 2026, up 16.3% on the year before. Over five years, revenue changed +16.9% a year on average.
- Its operating margin was 28.7%, up 3.5 pts: of every 100 in sales, about 29 is left after running the business.
- Veeva Systems made $909M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew 29.5% a year.
- Free cash flow was $1.4B in fiscal 2026, 43.4% of revenue.
- Veeva Systems returned $170M to shareholders in fiscal 2026, 12% of free cash flow. The diluted share count rose 1.1%.
- Veeva Systems has $6.6B more cash than debt.
Market cap
$52.5B
P/E
52.1x
Revenue
$3.2B
Net income
$909M
Free cash flow
$1.4B
Operating margin
28.7%
Veeva Systems in 30 seconds · fiscal 2026
Are sales growing?
+16.3%
Yes. Sales grew 16.3% last year.
Does it make a profit?
28.4%
Yes. It keeps 28.4% of every sale as profit.
Does profit turn into cash?
43.4%
Yes. 43.4% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
6 / 9
Mixed. It passes 6 of 9 health tests.
How is the share priced?
52.1x
One share costs 52.1 times its yearly profit per share. Typical for its sector: 27.9x.
What Veeva Systems does
No business description yet.
- Fiscal year ends
- January 31, 2026
- Latest annual report
- 10-K · Mar 20, 2026
- Legal name
- Veeva Systems Inc.
- CIK
- 0001393052
Veeva Systems · VEEV
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $1.9B | $2.2B | $2.4B | $2.7B | $3.2B |
| Revenue growth | 26.3% | 16.4% | 9.7% | 16.2% | 16.3% |
| Gross margin | 72.8% | 71.7% | 71.4% | 74.5% | 75.5% |
| Operating margin | 27.3% | 21.3% | 18.2% | 25.2% | 28.7% |
| Net income | $427M | $488M | $526M | $714M | $909M |
| Net margin | 23.1% | 22.6% | 22.2% | 26.0% | 28.4% |
| Diluted EPS | $2.63 | $3.00 | $3.22 | $4.32 | $5.44 |
| Cash | |||||
| Cash from operations | $765M | $781M | $911M | $1.1B | $1.4B |
| Capital expenditure | $14.2M | $13.5M | $26.2M | $20.5M | $29.1M |
| Free cash flow | $750M | $767M | $885M | $1.1B | $1.4B |
| FCF margin | 40.5% | 35.6% | 37.5% | 38.9% | 43.4% |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $170M |
| Share count change | 1.0% | 0.1% | 0.7% | 1.1% | 1.1% |
| Debt and strength | |||||
| Cash and short-term investments | $2.4B | $3.1B | $4.0B | $5.2B | $6.6B |
| Debt incl. finance leases | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $2.9B | $3.7B | $4.6B | $5.8B | $7.2B |
| Net debt / EBITDA | −4.5x | −6.4x | −8.7x | −7.1x | −6.9x |
| Current ratio | 3.7x | 3.9x | 4.2x | 4.5x | 4.9x |
| Returns and quality | |||||
| Return on capital | 74.1% | 76.5% | 62.4% | — | — |
| Return on equity | 16.5% | 14.7% | 12.6% | 13.6% | 13.9% |
| Piotroski F-score | 5 | 4 | 4 | 6 | 6 |
| Altman Z'' | 9.6 | 9.8 | 10.1 | 10.6 | 11.2 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$16.8M
4 insiders
Of sales under plans
91%
$15.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Veeva Systems · VEEV
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
Similar companies
Each company’s latest fiscal year. Fiscal years end in different months, so periods don’t line up exactly.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score |
|---|---|---|---|---|---|---|---|
| Veeva Systems VEEV | $52.5B | 16.3% | 28.7% | 43.4% | — | 52.1x | 6 |
| Solventum SOLV | $14.9B | 0.9% | 26.2% | −0.1% | 20.4% | 10.5x | 5 |
| Doximity DOCS | $6.3B | 13.1% | 33.3% | 50.6% | 91.3% | 38.9x | 4 |
| Certara CERT | $1.6B | 8.8% | 5.0% | 22.6% | 0.9% | — | 5 |
| HealthStream HSTM | $1.0B | 4.3% | 6.7% | 19.6% | — | 48.4x | — |
Price compared with profit (P/E)
How many times its yearly profit per share one share costs. Higher means investors pay more for each unit of profit.
KIRA
At $318.18 a share, the company is worth $52.5B: 52.1 times its earnings of the last four quarters.
Veeva Systems grew sales faster than 4 of its 4 similar companies. Its P/E is higher than 3 of 3.
Source: SEC EDGAR XBRL filings (CIK 0001393052). Data updated October 9, 2026. For information only — not investment advice. Check the original filings before relying on any figure.